Actively Recruiting
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Led by Canadian Cancer Trials Group · Updated on 2026-02-02
84
Participants Needed
18
Research Sites
217 weeks
Total Duration
On this page
Sponsors
C
Canadian Cancer Trials Group
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
CONDITIONS
Official Title
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of classical Hodgkin lymphoma confirmed by tissue analysis and now have relapsed or refractory disease after anthracycline chemotherapy
- Age 18 years or older
- ECOG performance status of 0 or 1
- Measurable disease by clinical or radiological methods according to Lugano 2014 criteria
- Life expectancy greater than 90 days
- Blood counts and organ function within specified limits
- Able and willing to complete quality of life questionnaires in English or French
- Signed informed consent according to local regulations
- Available for treatment and follow-up
- Protocol treatment to begin within 2 working days of enrollment
- Women and men of childbearing potential agree to use highly effective contraception during the study and for 6 months after treatment
- Tumor tissue block from original and relapse biopsy available or pathology reports submitted if biopsy not accessible
You will not qualify if you...
- Prior salvage systemic therapy for relapsed or refractory disease
- History of peripheral neuropathy or shortness of breath grade 2 or higher
- History of other cancers except certain treated skin, bladder, cervical, breast, or prostate cancers with no evidence of disease for over 3 years
- Active central nervous system disease
- Diagnosis of immunodeficiency or recent systemic steroid or immunosuppressive therapy
- Active autoimmune disease requiring systemic treatment in past 3 years or history of allogeneic transplant
- Known HIV infection, active hepatitis B or C infection, or uncontrolled active systemic infection
- Significant cardiovascular disease including recent heart attack or heart failure
- History of stroke or transient ischemic attack
- History of progressive multifocal leukoencephalopathy
- Serious medical or psychiatric conditions that prevent safe treatment or follow-up
- Recent vaccination with live attenuated vaccines within 4 weeks
- Pregnant or breastfeeding women or those not willing to use birth control
- Prior infusion reactions to study drugs greater than grade 2
- History or current pneumonitis requiring steroids
- History of allogenic tissue or solid organ transplant
- Recent treatment with other investigational or anti-cancer drugs
- Recent radiotherapy within 2 weeks before study treatment start with unresolved toxicities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Concord Repatriation General Hospital
Concord, New South Wales, Australia, 2139
Actively Recruiting
2
Shoalhaven Cancer Care Centre
Nowra, New South Wales, Australia, 2541
Actively Recruiting
3
Wollongong Hospital
Wollongong, New South Wales, Australia, 2500
Actively Recruiting
4
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Actively Recruiting
5
Austin Hospital
Heidelberg, Victoria, Australia, 3084
Actively Recruiting
6
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Actively Recruiting
7
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada, T2N 5G2
Actively Recruiting
8
BCCA - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
9
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Actively Recruiting
10
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H 1V7
Actively Recruiting
11
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
Actively Recruiting
12
London Health Sciences Centre Research Inc.
London, Ontario, Canada, N6A 5W9
Actively Recruiting
13
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
14
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
15
The Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
16
The Research Institute of the McGill University
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
17
CIUSSS de l'Estrie - Centre hospitalier
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
18
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
Actively Recruiting
Research Team
A
Annette Hay
CONTACT
L
Lois Shepherd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here